ES2686631T3 - Determinaciones de cáncer de pulmón utilizando relaciones de miARN - Google Patents
Determinaciones de cáncer de pulmón utilizando relaciones de miARN Download PDFInfo
- Publication number
- ES2686631T3 ES2686631T3 ES14827245.3T ES14827245T ES2686631T3 ES 2686631 T3 ES2686631 T3 ES 2686631T3 ES 14827245 T ES14827245 T ES 14827245T ES 2686631 T3 ES2686631 T3 ES 2686631T3
- Authority
- ES
- Spain
- Prior art keywords
- mirna
- expression
- mir
- ratio
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091070501 miRNA Proteins 0.000 title claims abstract description 607
- 239000002679 microRNA Substances 0.000 title claims abstract description 487
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 210
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 80
- 201000005202 lung cancer Diseases 0.000 title claims description 79
- 230000014509 gene expression Effects 0.000 claims abstract description 264
- 208000037841 lung tumor Diseases 0.000 claims abstract description 128
- 238000000034 method Methods 0.000 claims abstract description 112
- 239000012472 biological sample Substances 0.000 claims abstract description 34
- 239000000523 sample Substances 0.000 claims description 163
- 206010018910 Haemolysis Diseases 0.000 claims description 70
- 230000008588 hemolysis Effects 0.000 claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 210000002381 plasma Anatomy 0.000 claims description 47
- 108091027943 miR-16 stem-loop Proteins 0.000 claims description 15
- 108091039994 miR-486 stem-loop Proteins 0.000 claims description 15
- 108091034121 miR-92a stem-loop Proteins 0.000 claims description 15
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 claims description 15
- 230000002685 pulmonary effect Effects 0.000 claims description 13
- 108091028066 Mir-126 Proteins 0.000 claims description 11
- 108091028049 Mir-221 microRNA Proteins 0.000 claims description 10
- 238000002591 computed tomography Methods 0.000 claims description 10
- 108091031326 miR-15b stem-loop Proteins 0.000 claims description 10
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 10
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims description 10
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims description 10
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims description 10
- 108091063344 miR-30b stem-loop Proteins 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 108091060382 miR-140 stem-loop Proteins 0.000 claims description 5
- 108091030617 miR-140-1 stem-loop Proteins 0.000 claims description 5
- 108091023370 miR-140-2 stem-loop Proteins 0.000 claims description 5
- 238000010240 RT-PCR analysis Methods 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 238000010195 expression analysis Methods 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims description 2
- 238000009534 blood test Methods 0.000 claims description 2
- 238000013276 bronchoscopy Methods 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 239000013615 primer Substances 0.000 description 97
- 239000002987 primer (paints) Substances 0.000 description 80
- 238000001514 detection method Methods 0.000 description 48
- 230000035945 sensitivity Effects 0.000 description 37
- 238000012360 testing method Methods 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 21
- 108020004707 nucleic acids Proteins 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 238000003556 assay Methods 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 16
- 230000003321 amplification Effects 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000000391 smoking effect Effects 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- -1 amplified miRNAs Chemical class 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000002798 spectrophotometry method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108091069017 Homo sapiens miR-140 stem-loop Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000011179 visual inspection Methods 0.000 description 5
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- 108091069085 Homo sapiens miR-126 stem-loop Proteins 0.000 description 4
- 108091068993 Homo sapiens miR-142 stem-loop Proteins 0.000 description 4
- 108091069002 Homo sapiens miR-145 stem-loop Proteins 0.000 description 4
- 108091070489 Homo sapiens miR-17 stem-loop Proteins 0.000 description 4
- 108091067982 Homo sapiens miR-197 stem-loop Proteins 0.000 description 4
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 description 4
- 108091067572 Homo sapiens miR-221 stem-loop Proteins 0.000 description 4
- 108091070397 Homo sapiens miR-28 stem-loop Proteins 0.000 description 4
- 108091061672 Homo sapiens miR-660 stem-loop Proteins 0.000 description 4
- 108091008065 MIR21 Proteins 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 208000002458 carcinoid tumor Diseases 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000003849 large cell carcinoma Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 3
- 108091068999 Homo sapiens miR-144 stem-loop Proteins 0.000 description 3
- 108091070519 Homo sapiens miR-19b-1 stem-loop Proteins 0.000 description 3
- 108091070495 Homo sapiens miR-19b-2 stem-loop Proteins 0.000 description 3
- 108091067482 Homo sapiens miR-205 stem-loop Proteins 0.000 description 3
- 108091065163 Homo sapiens miR-30c-1 stem-loop Proteins 0.000 description 3
- 108091067641 Homo sapiens miR-30c-2 stem-loop Proteins 0.000 description 3
- 108091067007 Homo sapiens miR-324 stem-loop Proteins 0.000 description 3
- 108091070381 Homo sapiens miR-92a-2 stem-loop Proteins 0.000 description 3
- 206010027540 Microcytosis Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 108091068840 Homo sapiens miR-101-1 stem-loop Proteins 0.000 description 2
- 108091068941 Homo sapiens miR-106a stem-loop Proteins 0.000 description 2
- 108091067654 Homo sapiens miR-148a stem-loop Proteins 0.000 description 2
- 108091069045 Homo sapiens miR-15b stem-loop Proteins 0.000 description 2
- 108091070491 Homo sapiens miR-16-1 stem-loop Proteins 0.000 description 2
- 108091068927 Homo sapiens miR-16-2 stem-loop Proteins 0.000 description 2
- 108091069457 Homo sapiens miR-200b stem-loop Proteins 0.000 description 2
- 108091067468 Homo sapiens miR-210 stem-loop Proteins 0.000 description 2
- 108091070365 Homo sapiens miR-30a stem-loop Proteins 0.000 description 2
- 108091069021 Homo sapiens miR-30b stem-loop Proteins 0.000 description 2
- 108091067650 Homo sapiens miR-30d stem-loop Proteins 0.000 description 2
- 108091060457 Homo sapiens miR-320b-1 stem-loop Proteins 0.000 description 2
- 108091062096 Homo sapiens miR-320b-2 stem-loop Proteins 0.000 description 2
- 108091078081 Homo sapiens miR-320d-1 stem-loop Proteins 0.000 description 2
- 108091078082 Homo sapiens miR-320d-2 stem-loop Proteins 0.000 description 2
- 108091072689 Homo sapiens miR-320e stem-loop Proteins 0.000 description 2
- 108091065451 Homo sapiens miR-34b stem-loop Proteins 0.000 description 2
- 108091032930 Homo sapiens miR-429 stem-loop Proteins 0.000 description 2
- 108091032683 Homo sapiens miR-451a stem-loop Proteins 0.000 description 2
- 108091093123 Homo sapiens miR-451b stem-loop Proteins 0.000 description 2
- 108091053840 Homo sapiens miR-486 stem-loop Proteins 0.000 description 2
- 108091059229 Homo sapiens miR-486-2 stem-loop Proteins 0.000 description 2
- 108091064449 Homo sapiens miR-518e stem-loop Proteins 0.000 description 2
- 108091067630 Homo sapiens miR-7-2 stem-loop Proteins 0.000 description 2
- 108091070380 Homo sapiens miR-92a-1 stem-loop Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108091028684 Mir-145 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000006385 lung benign neoplasm Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 108091079012 miR-133a Proteins 0.000 description 2
- 108091024038 miR-133a stem-loop Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- YOSZEPWSVKKQOV-UHFFFAOYSA-N 12h-benzo[a]phenoxazine Chemical class C1=CC=CC2=C3NC4=CC=CC=C4OC3=CC=C21 YOSZEPWSVKKQOV-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 108091065458 Homo sapiens miR-101-2 stem-loop Proteins 0.000 description 1
- 108091068990 Homo sapiens miR-133a-1 stem-loop Proteins 0.000 description 1
- 108091068988 Homo sapiens miR-133a-2 stem-loop Proteins 0.000 description 1
- 108091060471 Homo sapiens miR-320c-1 stem-loop Proteins 0.000 description 1
- 108091078079 Homo sapiens miR-320c-2 stem-loop Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 108091060302 Mir-320 Proteins 0.000 description 1
- 208000002406 Mucoepidermoid Tumor Diseases 0.000 description 1
- 101100450263 Mus musculus Hadh gene Proteins 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035603 Pleural mesothelioma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000013154 diagnostic monitoring Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000001000 lipidemic effect Effects 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108091064157 miR-106a stem-loop Proteins 0.000 description 1
- 108091079658 miR-142-1 stem-loop Proteins 0.000 description 1
- 108091071830 miR-142-2 stem-loop Proteins 0.000 description 1
- 108091027034 miR-148a stem-loop Proteins 0.000 description 1
- 108091091751 miR-17 stem-loop Proteins 0.000 description 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 1
- 108091088515 miR-197 stem-loop Proteins 0.000 description 1
- 108091037787 miR-19b stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091039812 miR-28 stem-loop Proteins 0.000 description 1
- 108091055059 miR-30c stem-loop Proteins 0.000 description 1
- 108091063151 miR-660 stem-loop Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 238000007842 plasma-based assay Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923758P | 2014-01-05 | 2014-01-05 | |
| US201461923758P | 2014-01-05 | ||
| US201461926323P | 2014-01-12 | 2014-01-12 | |
| US201461926323P | 2014-01-12 | ||
| PCT/EP2014/079499 WO2015101653A1 (en) | 2014-01-05 | 2014-12-31 | Lung cancer determinations using mirna ratios |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2686631T3 true ES2686631T3 (es) | 2018-10-18 |
Family
ID=52347306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14827245.3T Active ES2686631T3 (es) | 2014-01-05 | 2014-12-31 | Determinaciones de cáncer de pulmón utilizando relaciones de miARN |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20150191794A1 (https=) |
| EP (2) | EP3090059B1 (https=) |
| JP (2) | JP6706208B2 (https=) |
| CN (1) | CN106164290A (https=) |
| AU (1) | AU2014375224A1 (https=) |
| BR (1) | BR112016015595A2 (https=) |
| CA (1) | CA2935789A1 (https=) |
| ES (1) | ES2686631T3 (https=) |
| IL (1) | IL246580B (https=) |
| WO (1) | WO2015101653A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11535895B2 (en) * | 2017-04-06 | 2022-12-27 | University Of Maryland, Baltimore | Methods of detecting lung cancer |
| JP6884810B2 (ja) * | 2019-05-08 | 2021-06-09 | キユーピー株式会社 | 情報提供装置、情報提供方法及びｍｉＲＮＡ重要度テーブル生成方法 |
| IT202100008798A1 (it) * | 2021-04-08 | 2022-10-08 | Univ Degli Studi Di Ferrara | Uso del microrna hsa-mir-197-3p come marcatore di esposizione all’amianto e di mesotelioma maligno della pleura |
| CN113278692A (zh) * | 2021-05-19 | 2021-08-20 | 北京艾克伦医疗科技有限公司 | 鉴定肺结节状态的方法和试剂盒 |
| US20250059603A1 (en) * | 2021-12-15 | 2025-02-20 | Sera Prognastics, Inc. | Expanded panels of nucleic acid biomarkers for placental dysfunction |
| WO2025089028A1 (ja) * | 2023-10-24 | 2025-05-01 | アークレイ株式会社 | 検査方法、検査装置、検査システム、検査プログラム、記録媒体、及び溶血程度学習済モデルの生成方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366860A (en) | 1989-09-29 | 1994-11-22 | Applied Biosystems, Inc. | Spectrally resolvable rhodamine dyes for nucleic acid sequence determination |
| US5188934A (en) | 1989-11-14 | 1993-02-23 | Applied Biosystems, Inc. | 4,7-dichlorofluorescein dyes as molecular probes |
| DE69131891T2 (de) | 1990-02-16 | 2000-06-15 | F. Hoffmann-La Roche Ag, Basel | Verbesserungen in der spezifität und zweckmässigkeit der polymerase-kettenreaktion |
| US5965364A (en) | 1990-10-09 | 1999-10-12 | Benner; Steven Albert | Method for selecting functional deoxyribonucleotide derivatives |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5413924A (en) | 1992-02-13 | 1995-05-09 | Kosak; Kenneth M. | Preparation of wax beads containing a reagent for release by heating |
| US5767259A (en) | 1994-12-27 | 1998-06-16 | Naxcor | Oligonucleotides containing base-free linking groups with photoactivatable side chains |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| CA2168712A1 (en) | 1995-02-07 | 1996-08-08 | John William Henderson Sutherland | Use of exonuclease and/or glycosylase as supplements to anti-polymerase antibody to increase specificity in polymerase chain reaction |
| US6020481A (en) | 1996-04-01 | 2000-02-01 | The Perkin-Elmer Corporation | Asymmetric benzoxanthene dyes |
| EP0892808B1 (en) | 1996-04-12 | 2008-05-14 | PHRI Properties, Inc. | Detection probes, kits and assays |
| US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
| US5863727A (en) | 1996-05-03 | 1999-01-26 | The Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
| US5847162A (en) | 1996-06-27 | 1998-12-08 | The Perkin Elmer Corporation | 4, 7-Dichlororhodamine dyes |
| US5945526A (en) | 1996-05-03 | 1999-08-31 | Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
| SE506700C2 (sv) | 1996-05-31 | 1998-02-02 | Mikael Kubista | Sond och förfaranden för analys av nukleinsyra |
| US6008379A (en) | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
| ATE478090T1 (de) | 1997-10-27 | 2010-09-15 | Boston Probes Inc | SICH AUF ßPNA MOLECULAR BEACONSß BEZIEHENDE VERFAHREN, TESTSÄTZE UND ZUSAMMENSETZUNGEN |
| US6485901B1 (en) | 1997-10-27 | 2002-11-26 | Boston Probes, Inc. | Methods, kits and compositions pertaining to linear beacons |
| US5936087A (en) | 1997-11-25 | 1999-08-10 | The Perkin-Elmer Corporation | Dibenzorhodamine dyes |
| US6140054A (en) | 1998-09-30 | 2000-10-31 | University Of Utah Research Foundation | Multiplex genotyping using fluorescent hybridization probes |
| US6383752B1 (en) | 1999-03-31 | 2002-05-07 | Hybridon, Inc. | Pseudo-cyclic oligonucleobases |
| YU72901A (sh) * | 1999-04-02 | 2004-07-15 | Corixa Corporation | Preparati za primenu u terapiji i dijagnozi raka pluća |
| MXPA02000192A (es) * | 1999-06-30 | 2004-08-12 | Corixa Corp | Composiciones y metodos para la terapia y diagnostico de cancer de pulmon. |
| CN101284873A (zh) * | 1999-06-30 | 2008-10-15 | 科里克萨有限公司 | 用于肺癌治疗和诊断的组合物和方法 |
| US6140500A (en) | 1999-09-03 | 2000-10-31 | Pe Corporation | Red-emitting [8,9]benzophenoxazine nucleic acid dyes and methods for their use |
| US6528254B1 (en) | 1999-10-29 | 2003-03-04 | Stratagene | Methods for detection of a target nucleic acid sequence |
| US6191278B1 (en) | 1999-11-03 | 2001-02-20 | Pe Corporation | Water-soluble rhodamine dyes and conjugates thereof |
| US6596490B2 (en) | 2000-07-14 | 2003-07-22 | Applied Gene Technologies, Inc. | Nucleic acid hairpin probes and uses thereof |
| US6350580B1 (en) | 2000-10-11 | 2002-02-26 | Stratagene | Methods for detection of a target nucleic acid using a probe comprising secondary structure |
| US6403341B1 (en) | 2001-08-02 | 2002-06-11 | Wayne M. Barnes | Magnesium precipitate hot start method for PCR |
| AU2002334307A1 (en) | 2001-09-04 | 2003-03-18 | Exiqon A/S | Novel lna compositions and uses thereof |
| US6593091B2 (en) | 2001-09-24 | 2003-07-15 | Beckman Coulter, Inc. | Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer |
| US20060078894A1 (en) | 2004-10-12 | 2006-04-13 | Winkler Matthew M | Methods and compositions for analyzing nucleic acids |
| US7993831B2 (en) * | 2007-09-14 | 2011-08-09 | Asuragen, Inc. | Methods of normalization in microRNA detection assays |
| JP2011505143A (ja) * | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング |
| EP2470897A4 (en) * | 2009-08-28 | 2013-05-29 | Asuragen Inc | MICRO-RNA BIOMARKERS OF PULMONARY DISEASE |
| SG2014010698A (en) * | 2009-11-02 | 2014-05-29 | Agency Science Tech & Res | Methods of monitoring cellular states |
| HRP20191481T1 (hr) * | 2011-02-07 | 2019-11-15 | Gabriella Sozzi | Mikro-rnk biomarkeri za identificiranje rizika i/ili dijagnosticiranje tumora pluća |
| WO2013063519A1 (en) * | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
-
2014
- 2014-12-31 AU AU2014375224A patent/AU2014375224A1/en not_active Abandoned
- 2014-12-31 JP JP2016562064A patent/JP6706208B2/ja not_active Expired - Fee Related
- 2014-12-31 CN CN201480076735.0A patent/CN106164290A/zh active Pending
- 2014-12-31 BR BR112016015595A patent/BR112016015595A2/pt not_active IP Right Cessation
- 2014-12-31 EP EP14827245.3A patent/EP3090059B1/en active Active
- 2014-12-31 US US14/587,281 patent/US20150191794A1/en not_active Abandoned
- 2014-12-31 CA CA2935789A patent/CA2935789A1/en not_active Abandoned
- 2014-12-31 EP EP18175641.2A patent/EP3425066A1/en not_active Withdrawn
- 2014-12-31 WO PCT/EP2014/079499 patent/WO2015101653A1/en not_active Ceased
- 2014-12-31 ES ES14827245.3T patent/ES2686631T3/es active Active
-
2016
- 2016-07-03 IL IL246580A patent/IL246580B/en active IP Right Grant
- 2016-12-19 US US15/383,932 patent/US20170204467A1/en not_active Abandoned
-
2018
- 2018-05-16 US US15/981,640 patent/US20190119756A1/en not_active Abandoned
-
2019
- 2019-04-30 JP JP2019087056A patent/JP2019122412A/ja active Pending
-
2020
- 2020-11-13 US US17/097,408 patent/US20210301350A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2935789A1 (en) | 2015-07-09 |
| JP2019122412A (ja) | 2019-07-25 |
| WO2015101653A1 (en) | 2015-07-09 |
| JP2017502699A (ja) | 2017-01-26 |
| CN106164290A (zh) | 2016-11-23 |
| IL246580A0 (en) | 2016-08-31 |
| JP6706208B2 (ja) | 2020-06-03 |
| EP3090059B1 (en) | 2018-06-06 |
| US20210301350A1 (en) | 2021-09-30 |
| EP3090059A1 (en) | 2016-11-09 |
| US20150191794A1 (en) | 2015-07-09 |
| AU2014375224A1 (en) | 2016-07-28 |
| US20170204467A1 (en) | 2017-07-20 |
| BR112016015595A2 (pt) | 2017-10-24 |
| US20190119756A1 (en) | 2019-04-25 |
| IL246580B (en) | 2020-11-30 |
| EP3425066A1 (en) | 2019-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6203209B2 (ja) | 早期結腸直腸癌の検出のための血漿マイクロｒｎａ | |
| CN110799648B (zh) | 用于检测肺癌的试剂盒、装置和方法 | |
| Giráldez et al. | Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study | |
| Kurashige et al. | Serum microRNA‐21 is a novel biomarker in patients with esophageal squamous cell carcinoma | |
| ES2686631T3 (es) | Determinaciones de cáncer de pulmón utilizando relaciones de miARN | |
| US10457994B2 (en) | 4-miRNA signature for predicting clear cell renal cell carcinoma metastasis and prognosis | |
| CN102876676B (zh) | 一种与胰腺癌相关的血清/血浆miRNA标志物及其应用 | |
| CN103930563A (zh) | 用于预测癌症复发的方法和装置 | |
| JP7045527B2 (ja) | 肝機能障害の予測のためのマイクロｒｎａシグネチャ | |
| Ueda et al. | Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network analysis | |
| US20130084241A1 (en) | DEVELOPMENT OF miRNA DIAGNOSTICS TOOLS IN BLADDER CANCER | |
| WO2016077858A1 (en) | Biomarkers of disease and their use in disease detection and management | |
| US10519506B2 (en) | Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer | |
| US20150133330A1 (en) | Methods and compositions useful for diagnosing inflammatory bowel disease-associated neoplasia | |
| US20250092460A1 (en) | Circulating microrna signatures for pancreatic cancer | |
| Jiang et al. | Signatures containing miR-133a identified by large scale miRNA profiling in bladder cancer | |
| WO2023115601A1 (zh) | 一种用于结直肠癌预后的miRNA检测试剂盒 |